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To the Editor: Buruli ulcer caused
by Mycobacterium ulcerans was rec-
ognized in 1997 as an emerging public
health problem by the World Health
Organization (WHO) (1). The disease
is found in tropical Africa, the
Americas, Australia, and Asia (2). In
Benin, severe disease with serious
complications is reported with increas-
ing frequency. Buruli ulcer causes
serious deformities and disability, par-
ticularly since amputating limbs is
sometimes required in cases of severe
disease such as osteomyelitis (3).
Given the effect on the quality of life
of those afflicted and the lack of ade-
quate treatment, identifying host risk
factors for Buruli ulcer is an important
research imperative (2). We investigat-
ed one potential risk factor, concurrent
infection with Schistosoma haemato-
bium. Preliminary data indicate that
although S. haematobium is not a risk
factor for Buruli ulcer, it may be asso-
ciated with osteomyelitis.
Although Buruli ulcer and schisto-
somiasis each exist in the absence of
the other, close parallels exist between
their epidemiology, suggesting that
schistosomiasis could be one possible
risk factor for Buruli ulcer. Both dis-
eases are associated with the tropical
wetlands of west and central Africa.
Cases of both schistosomiasis and
Buruli ulcer have increased rapidly in
these areas since the 1980s, particu-
larly after irrigation and dam con-
struction. Buruli ulcer is most fre-
quent in children <15 years of age;
this group typically also has the high-
est prevalence and intensity of schis-
tosome infections. Schistosomiasis is
transmitted through contact with
infected water when the cercarial lar-
vae penetrate skin, and increasing evi-
dence exists that M. ulcerans prolifer-
ates in the bottom mud of stagnant
waters and may be harbored by aquat-
ic insects (4). 
An immunologic rationale for
linking the two diseases has been pro-
posed (5). Briefly, protective immune
responses to other mycobacterial dis-
eases are known to depend on a type 1
cellular response, typified by interfer-
on-gamma (IFN-γ). Helminth infec-
tions, on the other hand, are classical-
ly associated with type 2 responses,
typified by interleukin (IL)-4 and IL-
5 production. Therefore, a concurrent
infection with a bloodborne helminth
such as S. haematobium may skew the
immune response away from a poten-
tially protective type 1 response (5). 
A total of 113 patients were
recruited from Buruli ulcer treatment
centers in Lalo (Couffo Department)
and Zagnanado (Zou Department) in
Benin. A team of experienced sur-
geons clinically confirmed all cases of
Buruli ulcer. Controls (n = 429) were
recruited at random from residents of
eight current Buruli ulcer foci in the
Couffo Department. Past or current
Buruli ulcer patients were excluded
from the lottery for controls.
Clinical records reported no case
of intestinal schistosomiasis in this
area. This finding was confirmed by a
preliminary survey of 60 Buruli ulcer
patients, which detected no concur-
rent S. mansoni by using the Kato
Katz method (6). Diagnosis of S.
haematobium (urinary schistosomia-
sis) was performed by filtering three
urine samples given on different days.
Neither cases nor controls were asked
to exercise (as is usual) before giving
urine samples because many Buruli
ulcer cases were immobile. All
patients positive for S. haematobium
were offered praziquantel treatment. 
In the entire participating popula-
tion, 11.5% (95% confidence interval
[CI] 6% to 19%) of Buruli ulcer cases
were positive for S. haematobium;
11.1% (95% CI 5% to 20%) of cases
from Lalo and 12.2% (95% CI 4% to
26%) from Zagnanado were positive.
The difference between the two cen-
ters was not statistically significant. Of
the 429 non-Buruli ulcer controls,
9.5% (95% CI 7% to 13%) were posi-
tive for S. haematobium. No statistical-
ly significant difference between cases
and controls was detected. The odds
ratio for S. haematobium infection in a
logistic regression model (which also
included age and sex) was 1.3 (95% CI
0.63 to 2.4). Prevalence of S. haemato-
bium infection did not significantly
differ between controls’ residence
(data not shown). Power analysis indi-
cates that about 4,000 cases and con-
trols would be required to find a statis-
tically significant difference at this
prevalence of schistosomiasis.
Both schistosomiasis and Buruli
ulcer are very local in nature; one vil-
lage can have substantial numbers of
cases whereas the next village could
have none. S. haematobium foci with
infection prevalence >50% do exist in
Benin but in different settlements
from the Buruli ulcer foci. Should a
Buruli ulcer focus coincide with a
schistosomiasis focus with a higher
prevalence of infection, some associa-
tion between the two diseases could
appear.
Detailed clinical information was
available for 36 patients tested for S.
haematobium. In all cases, at least two
of four laboratory tests were positive
for M. ulcerans. These tests were: 1)
acid-fast bacilli in a smear stained by
the Ziehl-Neelsen technique, 2) posi-
tive culture of M. ulcerans, 3)
histopathologic examination of a tis-
sue specimen, and 4) positive poly-
merase chain reaction (PCR) for M.
ulcerans DNA. Five patients had con-
firmed infection in bone samples, so
they were classified as osteomyelitis
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patients. Two of these five had con-
current S. haematobium, compared to
no cases in nonosteomyelitis patients;
a Fisher exact test showed this differ-
ence to be significant (p < 0.02).
These limited and preliminary data
are consistent with the relationship
between leprosy (caused by a
mycobacterium related to the one
causing Buruli ulcer, M. leprae) and
concurrent helminth infections. The
severity of leprosy has recently been
linked to intestinal helminth infection,
whereas the presence or absence of
leprosy has not (7). The cytokine envi-
ronment created by helminth infection
may facilitate disease progression to a
more severe form, or severe mycobac-
terial disease and helminth infection
may have a common risk factor.
We were unable to furnish evi-
dence of a link between the presence
or absence of S. haematobium infec-
tion and Buruli ulcer, but concurrent
infections could influence Buruli
ulcer clinical manifestation and dis-
ease severity.
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1998 Dengue
Hemorrhagic Fever
Epidemic in Taiwan 
To the Editor: The rapid spread-
ing of dengue viruses has led to
increasing incidence rates of dengue
fever (DF), dengue hemorrhagic fever
(DHF), and dengue shock syndrome
(DSS) worldwide in the past 20 years.
The global pandemic of DF and DHF
in 1998 was associated with the
largest DF epidemics many tropical or
subtropical countries had ever experi-
enced (1,2). Here we report the unique
epidemiologic characteristics of DF
and DHF caused by dengue virus type
3 (DEN-3) in Taiwan, where dengue
is not endemic. 
The recent epidemics of dengue in
Taiwan started when dengue virus
type 2 (DEN-2) was first introduced
into the southern off-islet of Hsiao-
Liu-Chiu in 1981 after an absence of
38 years since World War II. Tainan
City in southern Taiwan had not had a
dengue epidemic since l942–1943
until three dengue outbreaks occurred
there in the last decade. The first out-
break of DEN-1 in 1994 and the sec-
ond of DEN-2 in 1997 involved few
confirmed cases. The third epidemic
of dengue, which was attributed to
DEN-3, began in October 1998 and
continued into January 1999. 
From August 1, 1998, to January
31, 1999, physicians in all the hospi-
tals and clinics in Tainan City were
required to report any suspected
dengue cases who met the criteria of
fever (>38oC) and two or more of the
following symptoms and signs:
headache, retroorbital pain, myalgia,
arthralgia, rash, and hemorrhagic
manifestations. Patients who met the
criteria were invited to participate in
the study; informed consent was
given by the patients, and plasma or
serum samples were collected for lab-
oratory confirmation. When a physi-
cian reported a suspected dengue
case, a minimum of 100 blood sam-
ples would be collected from the
patient’s neighbors by the Tainan City
Health Bureau staff. The blood speci-
mens were transported to the labora-
tory at the National Institute of
Preventive Medicine for confirma-
tion. A confirmed dengue case was
required to be positive by either
reverse transcription–polymerase
reaction (3), or demonstrate serocon-
version by dengue-specific
immunoglobulin (Ig) M and seroneg-
ativity for Japanese encephalitis virus
(JEV)-specific IgM by IgM-enzyme-
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